FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Biblioteca de Peptídeos

ACE-031

ACVR2B-Fc / ActRIIB-Fc

Growth Factors

ACE-031 is a soluble form of the activin receptor type IIB (ActRIIB) fused to an IgG1 Fc domain, developed by Acceleron Pharma as a decoy receptor to trap myostatin and related TGF-beta ligands before they can signal through their natural receptors. By sequestering myostatin, activin A, and GDF-11, it was designed to promote muscle growth and inhibit muscle wasting. Clinical development was discontinued due to safety concerns including epistaxis and telangiectasias observed in Duchenne muscular dystrophy trials.

Mecanismo de Ação

Soluble activin receptor type IIB fusion protein that acts as a decoy receptor, binding and neutralizing myostatin, activin, GDF-11, and other TGF-beta superfamily ligands. Removes multiple negative regulators of muscle growth simultaneously.

Protocolos de Pesquisa

Para fins de pesquisa apenas. Não é conselhos médicos.

Clinical trial protocols used 0.3-3mg/kg intravenously every 2 weeks. Research was halted after Phase 2 due to epistaxis and telangiectasia in Duchenne muscular dystrophy patients.

Notas de Pesquisa

Clinical Research Status

ACE-031 completed a Phase 2 trial in boys with Duchenne muscular dystrophy (DMD) but was discontinued in 2011 after safety signals including nosebleeds, gum bleeding, and skin telangiectasias (dilated blood vessels) emerged. A Phase 1 trial in healthy postmenopausal women demonstrated dose-dependent increases in lean body mass and thigh muscle volume. Acceleron subsequently developed ACE-083 (a locally-acting version) and ACE-2494 with modified selectivity, though neither has achieved approval for muscle indications.

Key Published Findings

The Phase 1 trial showed a single dose of ACE-031 increased lean body mass by up to 1.0 kg and decreased fat mass, with sustained effects over 4 weeks post-dose. The DMD Phase 2 trial was halted after dose-limiting vascular effects (epistaxis, telangiectasia) were observed at higher doses. Research determined that the broad ligand-trapping profile, particularly inhibition of BMP-9 and BMP-10 (which regulate vascular homeostasis), caused the vascular adverse effects rather than myostatin inhibition itself.

Safety Profile

The primary safety concern was vascular effects attributed to BMP-9/10 inhibition: epistaxis (nosebleeds), telangiectasias, and gum bleeding, which are manifestations of disrupted vascular integrity similar to hereditary hemorrhagic telangiectasia. These vascular effects were dose-dependent and reversible upon discontinuation. The lesson from ACE-031's failure is that broadly targeting the ActRIIB ligand family produces unacceptable off-target vascular effects, necessitating more selective approaches to myostatin inhibition.

Comparison to Related Compounds

ACE-031's broad ligand trap approach contrasts with more selective myostatin-specific antibodies (stamulumab, domagrozumab) that avoid BMP-9/10 inhibition. Follistatin similarly neutralizes multiple TGF-beta family members but through a different mechanism and has not shown the same vascular toxicity pattern. Acceleron's subsequent ACE-083, a locally-injected compound, attempted to avoid systemic vascular effects but was also discontinued in FSHD trials due to insufficient efficacy.

Community Observations

ACE-031's clinical failure is frequently cited as a cautionary example of how broad-spectrum target approaches in the myostatin pathway carry unpredictable risks from inhibiting related ligands. The compound demonstrated that pure myostatin inhibition alone may not be sufficient for clinically meaningful muscle gains, while non-selective approaches produce unacceptable side effects. Researchers have largely moved toward more targeted approaches (anti-myostatin antibodies, bimagrumab targeting ActRII directly) informed by ACE-031's failure mode.

Meio-Vivo

~10-15 days

Reconstituição

Sterile saline for IV infusion

Armazenamento

Liofilizado

Store at -20C. Protect from light.

Reconstituído

Prepare fresh for each administration.

Situação Legal nos EUA

Research chemical (clinical trials halted)

Também Conhecido Como

ACVR2B-FcActRIIB-Fc

Perguntas frequentes

O que é ACE-031?

ACE-031 is a soluble form of the activin receptor type IIB (ActRIIB) fused to an IgG1 Fc domain, developed by Acceleron Pharma as a decoy receptor to trap myostatin and related TGF-beta ligands before they can signal through their natural receptors. By sequestering myostatin, activin A, and GDF-11, it was designed to promote muscle growth and inhibit muscle wasting. Clinical development was discontinued due to safety concerns including epistaxis and telangiectasias observed in Duchenne muscular dystrophy trials.

Como ACE-031 funciona?

Soluble activin receptor type IIB fusion protein that acts as a decoy receptor, binding and neutralizing myostatin, activin, GDF-11, and other TGF-beta superfamily ligands. Removes multiple negative regulators of muscle growth simultaneously.

Qual é o status regulatório de ACE-031 nos EUA?

Research chemical (clinical trials halted)

Qual é a meia-vida de ACE-031?

~10-15 days

Por quais outros nomes ACE-031 é conhecido?

ACVR2B-Fc, ActRIIB-Fc

Peptide Contacts fornece resumos baseados em pesquisas apenas para fins informativos. Não hospedamos, distribuímos ou endossamos documentação de fornecedores. Todas as certificações de análise completa, certificados GMP e comunicações de fornecedores devem ser solicitadas e verificadas diretamente pelo comprador. Nada nesta plataforma constitui conselhos legais, médicos ou profissionais. Os usuários são unicamente responsáveis por verificar as credenciais dos fornecedores e garantir a conformidade com todas as leis locais, estaduais e federais aplicáveis antes de adquirir qualquer química de pesquisa. O uso desta plataforma constitui aceitação plena da responsabilidade pessoal.

Leia a declaração completa